The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Media ReleaseEfti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The FDA approved Keytruda (pembrolizumab), which is a PD-1 inhibitor, for people who relapse after their first treatment or ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Ms Deanne Miller (General Counsel, Company Secretary, Chief Op. Officer) ...